Microtubules: A dynamic target in cancer therapy

IUBMB Life

Volumn 60, Issue 3, 2008, Pages 165-170

  Pasquier, Eddy ^a   Kavallaris, Maria ^a,b  

^a CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Cancer; Chemotherapy; Drug resistance; Microtubules; Tubulin binding agents

Indexed keywords

2 METHOXYESTRADIOL; ANTINEOPLASTIC AGENT; COMBRETASTATIN; DOCETAXEL; DOLASTATIN; EPOTHILONE DERIVATIVE; PACLITAXEL; TAXANE DERIVATIVE; TUBULIN; TUBULIN BINDING AGENT; UNCLASSIFIED DRUG; VINCA ALKALOID; TUBULIN MODULATOR;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER THERAPY; CELL CYCLE; CELL DEATH; CELL DIVISION; CELL PROLIFERATION; CYTOSKELETON; HUMAN; METAPHASE; MICROTUBULE ASSEMBLY; MITOSIS; NONHUMAN; PROTEIN PHOSPHORYLATION; REVIEW; CLINICAL TRIAL; DRUG RESISTANCE; METABOLISM; MICROTUBULE; NEOPLASM;

VINCA;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CYTOSKELETON; DRUG RESISTANCE, NEOPLASM; HUMANS; MICROTUBULES; NEOPLASMS; TUBULIN; TUBULIN MODULATORS;

EID: 44049097644     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.25     Document Type: Review

References (33)

1. Attard, G., Greystoke, A., Kaye, S., and De Bono, J. (2006) Update on tubulin-binding agents. Pathol. Biol. 54, 72-84.
2. Andre, N., and Meille, C. (2006) Taxanes in paediatric oncology: and now? Cancer Treat. Rev. 32, 65-73.
3. Hussain, M., Tangen, C. M., Lara, P. N. Jr., Vaishampayan, U. N., Petrylak, D. P., Colevas, A. D., Sakr, W. A., and Crawford, E. D. (2005) Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J. Clin. Oncol. 23, 8724-8729.
4. Green, M. R., Manikhas, G. M., Orlov, S., Afanasyev, B., Makhson, A. M., Bhar, P., and Hawkins, M. J. (2006) Abraxane, a novel Cremophorfree, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann. Oncol. 17, 1263-1268.
5. Kirschner, M., and Mitchison, T. (1986) Microtubule dynamics. Nature 324, 621.
6. Jordan, M. A., and Wilson, L. (2004) Microtubules as a target for anti-cancer drugs. Nat. Rev. Cancer 4, 253-265.
7. Honore, S., Pasquier, E., and Braguer, D. (2005) Understanding microtubule dynamics for improved cancer therapy. Cell Mol. Life Sci. 62, 3039-3056.
8. Khodiyar, V. K., Maltais, L. J., Sneddon, K. M., Smith, J. R., Shimoyama, M., Cabral, F., Dumontet, C., Dutcher, S. K., Harvey, R. J., Lafanechère, L., Murray, J. M., Nogales, E., Piquemal, D., Stanchi, F., Povey, S., and Lovering, R. C. (2007) A revised nomenclature for the human and rodent alpha-tubulin gene family. Genomics 90, 285-289. (Pubitemid 47039201)
9. Ferlini, C., Raspaglio, G., Cicchillitti, L., Mozetti, S., Prislei, S., Bartollino, S., and Scambia, G. (2007) Looking at drug resistance mechanisms for microtubule interacting drugs: does TUBB3 work? Curr. Cancer Drug Target 7, 325-334.
10. Kavallaris, M., Don, S., and Verrills, N. M. (2007) Microtubule- associated proteins and microtubule-interacting proteins: regulators of microtubule dynamics. In Microtubule Targets in Cancer Therapy (Fojo, A. T., ed.). pp. 81-102, The Humana Press, Totowa, NJ.
11. Jordan, M. A. (2002) Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr. Med. Chem. Anticancer Agents 2, 1-17.
12. Zhou, J., and Giannakakou, P. (2005) Targeting microtubules for cancer chemotherapy. Curr. Med. Chem. AntiCancer Agents 5, 65-71.
13. Drukman, S., and Kavallaris, M. (2002) Microtubule alterations and resistance to tubulin-binding agents (Review). Int. J. Oncol. 21, 621-628.
14. Verrills, N. M., and Kavallaris, M. (2005) Improving the targeting of tubulin-binding agents: lessons from drug resistance studies. Curr. Pharm. Des. 11, 1719-1733.
15. Kavallaris, M., Kuo, D. Y., Burkhart, C. A., Regl, D. L., Norris, M. D., Haber, M., and Horwitz, S. B. (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J. Clin. Invest. 100, 1282-1293.
16. Ferrandina, G., Zannoni, G. F., Martinelli, E., Paglia, A., Gallotta, V., Mozzetti, S., Scambia, G., and Ferlini, C. (2006) Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin. Cancer Res. 12, 2774-2779.
17. Gan, P. P., and Pasquier, E. M. K. (2007) Class III {beta}-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res. 67, 9356-9363.
18. Shalli, K., Brown, I., Heys, S. D., and Schofield, A. C. (2005) Alterations of beta-tubulin isotypes in breast cancer cells resistant to docetaxel. Faseb J. 19, 1299-1301. (Pubitemid 41113729)
19. Barlow, S. B., Gonzalez-Garay, M. L., and Cabral, F. (2002) Paclitaxel-dependent mutants have severely reduced microtubule assembly and reduced tubulin synthesis. J. Cell Sci. 115, 3469-3478.
20. Wang, Y., and Cabral, F. (2005) Paclitaxel resistance in cells with reduced beta-tubulin. Biochim. Biophys. Acta. 1744, 245-255.
21. Verrills, N. M., Flemming, C. L., Liu, M., Ivery, M. T., Cobon, G. S., Norris, M. D., Haber, M., and Kavallaris, M. (2003) Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions. Chem. Biol. 10, 597-607.
22. Nettles, J. H., Li, H., Cornett, B., Krahn, J. M., Snyder, J. P., and Downing, K. H. (2004) The binding mode of epothilone A on alpha,-beta-tubulin by electron crystallography. Science 305, 866-869. (Pubitemid 39038421)
23. Bulinski, J. C., and Gunderson, G. G. (1991) Stabilization and posttranslational modification of microtubules during cellular morphogenesis. BioEssays 13, 285-293.
24. Kavallaris, M., Tait, A. S., Walsh, B. J., He, L., Horwitz, S. B., Norris, M. D., and Haber, M. (2001) Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res. 61, 5803-5809. (Pubitemid 32769098)
25. Zhang, C. C., Yang, J. M., White, E., Murphy, M., Levine, A., and Hait, W. N. (1998) The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. Oncogene 16, 1617-1624. (Pubitemid 28159910)
26. Dumontet, C., Jaffrezou, J. P., Tsuchiya, E., Duran, G. E., Chen, G., Derry, W. B., Wilson, L., Jordan, M. A., and Sikic, B. I. (2004) Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization. Bull. Cancer 91, E81-E112.
27. Don, S., Verrills, N. M., Liaw, T. Y., Liu, M. L., Norris, M. D., Haber, M., and Kavallaris, M. (2004) Neuronal-associated microtubule proteins class III beta-tubulin and MAP2c in neuroblastoma: role in resistance to microtubule-targeted drugs. Mol. Cancer Ther. 3, 1137-1146.
28. Martello, L. A., Verdier-Pinard, P., Shen, H. J., He, L., Torres, K., Orr, G. A., and Horwitz, S. B. (2003) Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation. Cancer Res. 63, 1207-1213.
29. Verrills, N. M., Liem, N. L., Liaw, T. Y., Hood, B. D., Lock, R. B., and Kavallaris, M. (2006) Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia - an in vivo study. Proteomics 6, 1681-1694.
30. Rouzier, R., Rajan, R., Wagner, P., Hess, K. R., Gold, D. L., Stec, J., Ayers, M., Ross, J. S., Zhang, P., Buchholz, T. A., Kuerer, H., Green, M., Arun, B., Hortobagyi, G. N., Symmans, W. F., and Pusztai, L. (2005) Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc. Natl. Acad. Sci. USA 102, 8315-8320.
31. Verrills, N. M., Walsh, B. J., Cobon, G. S., Hains, P. G., and Kavallaris, M. (2003) Proteome analysis of vinca alkaloid response and resistance in acute lymphoblastic leukemia reveals novel cytoskeletal alterations. J. Biol. Chem. 278, 45082-45093.
32. Verrills, N. M., Po'uha, S. T., Liu, M. L., Liaw, T. Y., Larsen, M. R., Ivery, M. T., Marshall, G. M., Gunning, P. W., and Kavallaris, M. (2006) Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia. J. Natl. Cancer Inst. 98, 1363-1374.
33. Pasquier, E., Honore, S., and Braguer, D. (2006) Microtubule-targeting agents in angiogenesis: where do we stand? Drug Resistance Updates 9, 74-86.